Healthcare
63/100
63/100Is GILD-Gilead Sciences, a buy?
Saturday 4 July 2026
Why now: The stock just reclaimed its 50-day average and is close to a nearby resistance level, so it is in a reasonable spot to watch for a real improvement in demand. But the industry-relative trend is weak, so this is more of a “prove it” moment than a clean momentum pick.
Upside: If sentiment stabilizes and the stock can sustain a move above the recent resistance area, a reasonable long-term upside case is roughly 15% to 25% from the current price over the next 12 to 24 months. That upside depends on the HIV engine holding steady and newer areas contributing enough to re-rate the stock.
Risks: The biggest risk is that investors keep avoiding the broader healthcare group, leaving the stock stuck in a range even if operations are fine. A second risk is that deal-related charges or pipeline setbacks create more headline earnings noise and weigh on confidence.
Scorecard
Read:Strong metricsSolid metricsSelectiveCautionUnfavourableN/A
| Scorecard | 63/100 | |
|---|---|---|
| Company Detail | GILD - Gilead Sciences, Inc. | |
| Price as at 2 July 2026 | $131.27 | |
| Market cap | $163.0B | |
| Quality and Fundamental Score (100) | ||
| Breakout / Early-Momentum /20 | 12/20 | |
| Rev/EPS Momentum /20 | 12/20 | |
| Business Quality /15 | 12/15 | |
| Balance Sheet /15 | 11/15 | |
| Valuation /10 | 7/10 | |
| Industry Relative Strength /10 | 2/10 | |
| Macro / Sector Tailwind /10 | 7/10 | |
| Growth (mechanical) | ||
| Cash runway | Cash generative | |
| Revenue YoY | +2.4% | |
| EPS YoY | +1684.2% | |
| FCF YoY | -8.2% | |
| Gross margin | 78.8% | |
| Valuation & Trend | ||
| Trailing P/E | 17.9x | |
| Forward P/E | 13.6x | |
| RSI (14d) | 58 | |
| vs 50d SMA | +1.3% | |
| Support cushion | −1.7% | |
| Sentiment | ||
| Wall Street verdict | Aligned | |
| News tone | Quiet | |
| Dividend | 2.5% | |
How are these colored?
| Metric | Strong metrics | Solid metrics | Selective | Caution | Unfavourable |
|---|---|---|---|---|---|
| Overall score | ≥ 80 | 70-79 | 60-69 | 50-59 | < 50 |
| Business quality /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Balance sheet /15 | ≥ 12 | 10-11 | 8-9 | 6-7 | < 6 |
| Market cap | ≥ $20B | $5B-$20B | $2B-$5B | $1B-$2B | < $1B |
| Cash runway | ≥ 3 yr or cash generative | 1.5-3 yr | 0.75-1.5 yr | 0.25-0.75 yr | < 0.25 yr |
| Revenue YoY | ≥ 15% | 5-15% | 0-5% | -5-0% | < -5% |
| EPS YoY | ≥ 20% | 5-20% | 0-5% | -5-0% | < -5% |
| FCF YoY | ≥ 10% | 1-10% | 0-1% | -5-0% | < -5% |
| Gross margin | ≥ 60% | 40-60% | 25-40% | 10-25% | < 10% |
| Trailing P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| Forward P/E | < 15 | 15-25 | 25-35 | 35-40 | > 40 or neg |
| RSI (14d) | 50-70 | 45-50 or 70-75 | 40-45 or 75-78 | 30-40 or 78-80 | < 30 or > 80 |
| vs 50d SMA | +2% to +15% | 0-2% or 15-25% | -2-0% or 25-35% | -3--2% or 35-40% | < -3% or > 40% |
| Support cushion | 2-10% above | 0-2% | 10-15% | 15-20% | price below support |
| Wall Street verdict | Aligned | — | Mixed | — | Disagrees |
| News tone | Positive | — | Neutral / Mixed | — | Negative |
| Dividend | Yield ≥ 2% & growing | Growing | Flat payer ≥ 1% | Low / flat | Cutting |
Detailed Analysis — Saturday 4 July 2026
What they do
Gilead Sciences develops and sells prescription medicines, with its largest profit engine coming from HIV treatments and prevention products. It also sells therapies in oncology and liver disease, and it makes money primarily from product sales to healthcare systems worldwide.
Leadership
Daniel O’DayCEO
Daniel O’Day has been Chairman and Chief Executive Officer of Gilead Sciences since 2019.
Andrew DickinsonCFO
Andrew Dickinson is Chief Financial Officer of Gilead Sciences.
Summary thesis
- Gilead is a high-cash-flow drug company with a strong HIV franchise that can fund dividends, buybacks, and research over time.
- Recent results show steady revenue and strong profitability, which supports long-term durability.
- The problem today is not the cash engine; it is that the stock is lagging its sector and is still building a base rather than breaking out.
- For a long-term holder, it can still be worth watching, but it needs evidence that growth outside HIV is becoming more meaningful and that investor demand for the stock is improving.
Wall Street alignment
Wall Street: Aligned (3/4 signals positive)
Analyst consensus
Buy (1.69, 27 analysts) · +20% upside
Institutional ownership
92% institutions, insiders 0.1%
Short interest
1.9% of float short · 3.0 d-to-cover
Smart money tape
-1 net (acc 2 / dist 3, last 26d)
Recent news
No material news in the last 7 days.
Dividends
Yield (fwd)
2.50%
Latest (TTM)
$3.19
2025
$3.16
2024
$3.08
Payout ratio: 43%
Technicals
Price
$131.27
RSI (14d)
57.7
50d SMA
$129.60
200d SMA
$129.92
vs 50d SMA
+1.3%
vs 200d SMA
+1.0%
Support (swing low)
$129.00 −1.7%
20-day high (R)
$131.62 +0.3%
Next swing high (swing high)
$137.20 +4.5%
Close as of 2026-07-02.
Score breakdown
Scores 63 out of 100 — a mixed overall grade. Business quality and balance sheet scored highest. Valuation and sector fit were fair but not standout drivers. Relative strength versus its industry weighed on the total. I capped the score because the stock is in a weak industry-relative position right now and is not in a confirmed breakout. Even with solid cash flow, the market is not currently rewarding this neighborhood.
Component scores are on the scorecard above.
Momentum evidence
- Technically, GILD is not in a clean uptrend acceleration.
- It has only recently moved back above its 50-day average, is barely above its 200-day average, and it is still below its 52-week high by a wide margin.
- The key positive is that it is close to a clear near-term resistance level, which gives a simple “line in the sand” for improving demand.
- The key negative is weak industry relative strength, which often keeps breakouts from following through even when the company itself is doing okay.
Fundamental evidence
- In the quarter ended March 31, 2026, Gilead reported total revenues of about $6.96 billion and net income of about $2.02 billion, with operating cash flow of about $2.54 billion.
- It paid a quarterly dividend of $0.82 per share and continued share repurchases.
- On the balance sheet at March 31, 2026, it reported cash and cash equivalents of about $7.63 billion and marketable debt securities of about $1.00 billion.
- Total debt is large for a pharma company, but the business generates meaningful cash and has flexibility through portfolio management.
- A real red flag to keep in mind is that headline earnings can be distorted by large acquisition or collaboration charges; investors should focus on underlying operating results and cash generation rather than one-quarter earnings swings.
Cash runway: Cash generative (latest annual free cash flow is positive).
Valuation view
Valuation looks more like a mature large-cap drug company than a high-growth biotech, which can be fair if the HIV franchise remains durable and cash returns stay consistent. The catch is that weak relative strength suggests the market is not willing to pay up until it sees clearer growth beyond the core franchise.
Macro tailwind
If markets lean defensive or reward reliable cash flows and dividends, large profitable healthcare names like Gilead can hold up better than many cyclical sectors. That is a supportive backdrop, even if healthcare leadership is not strong right now.
What to watch
Upcoming (1–6 months)
- Next quarterly earnings report and any updates to full-year 2026 revenue and profit outlook.
Ongoing
- Whether the stock can clear and hold above $131.62 and whether its industry relative strength improves from a weak level.
Long-term case
Over a multi-year horizon, the long-term case rests on protecting the HIV franchise, expanding prevention and treatment demand, and building a second leg of growth in oncology and liver disease that is big enough to matter. If Gilead can do that while maintaining strong free cash flow, it can continue to compound through dividends, buybacks, and selective investment.
If the company cannot broaden growth beyond HIV, the stock may remain a “cash return” story that delivers income but limited price appreciation.
Risks & invalidation
Risks
- The company remains heavily dependent on HIV economics; any faster-than-expected erosion from competition, pricing pressure, or demand shifts would hit cash flow.
Breaks the thesis
- If the stock fails the recent 50-day reclaim and falls back below that level for multiple closes, it would signal that demand is still weak and the base is not ready.
Bottom line
Gilead is a solid, cash-generating drug company, but this is not a compelling long-term buy at this moment because the stock is lagging badly and the chart is still a base, not a real breakout. If you already own it for cash flow and dividends, it is defensible, but for new money I would wait for clearer evidence that the stock is being rewarded again. Until then, I would not buy this stock.